3R Pharma

Company Overview

Snapshot

Founded in February 2020 by Michael Rubinov, 3R Pharma operates with 1–10 employees. The company has raised $800,000 across 2 funding rounds from 5 investors. In February 2023, 3R Pharma received a follow-on investment from CanNegev.

Business overview

3R Pharma specializes in the development of high-end, complex cannabinoid-based pharmaceutical products for chronic ocular diseases. The company's core technology focuses on patent-pending cannabinoid-based medicines designed to offer novel treatment options for conditions that are currently underserved. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology, 3R Pharma serves the healthcare and pharmaceutical industries.

Strategic signal

In February 2023, 3R Pharma secured a follow-on investment from the Israeli Innovation Authority and CanNegev Incubator. This indicates continued validation of the company's research and development efforts in cannabinoid-based ophthalmic solutions, signaling ongoing support for its innovative approach to addressing chronic ocular diseases.

Company Intelligence Q&A

What is 3R Pharma's primary focus?

3R Pharma is focused on developing high-end and complex cannabinoid-based pharmaceutical products to address chronic ocular diseases for patients globally.

When was 3R Pharma founded?

3R Pharma was founded in February 2020.

Which investor provided a follow-on investment to 3R Pharma?

In February 2023, CanNegev provided a follow-on investment to 3R Pharma, alongside the Israeli Innovation Authority, as part of a funding round that validated the company's research and development efforts.

What was a significant early funding event for 3R Pharma?

In October 2021, 3R Pharma received a seed investment from investors including Israel Innovation Authority and OurCrowd.

What is the current status of 3R Pharma?

3R Pharma is Non-Active and ceased to operate in April 2026.